US 12251395
RNAS for complement inhibition
granted A61KA61K31/713A61P
Quick answer
US patent 12251395 (RNAS for complement inhibition) held by Apellis Pharmaceuticals, Inc. expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/713, A61P, A61P43/00